Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells

Оценка сопоставимости качества нейтрализующего антитела против SARS-CoV-2, полученного с использованием временно трансфицированных, мини-пуловых и одноклоновых клеток CHO
Zhihao Fu, Yanping Zhu, Wenbo Wang, Xiaojuan Yu, Jialiang Du, Chun‐Yu Liu, Gang Wu, Chuanfei Yu, Gangling Xu, Lan Wang, Cexiong Fu, Hongchuan Liu, Yuan Li, Meng Li, Sha Guo, Yalan Yang, Maoqin Duan, Yongfei Cui, Hui Feng
2021-12-20

Biological and immunological functionsChinese hamster ovary cellsJS016 monoclonal antibodyProduct comparability assessmentSARS-CoV-2-neutralizing antibody
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered a serious public health crisis worldwide, and considering the novelty of the disease, preventative and therapeutic measures alike are urgently needed. To accelerate such efforts, the development of JS016, a neutralizing monoclonal antibody directed against the SARS-CoV-2 spike protein, was expedited from a typical 12- to 18-month period to a 4-month period. During this process, transient Chinese hamster ovary cell lines are used to support preclinical, investigational new drug-enabling toxicology research, and early Chemistry, Manufacturing and Controls development; mini-pool materials to supply Phase 1 clinical trials; and a single-clone working cell bank for late-stage and pivotal clinical trials were successively adopted. Moreover, key process performance and product quality investigations using a series of orthogonal and state-of-the-art techniques were conducted to demonstrate the comparability of products manufactured using these three processes, and the results indicated that, despite observed variations in process performance, the primary and high-order structures, purity and impurity profiles, biological and immunological functions, and degradation behaviors under stress conditions were largely comparable. The study suggests that, in particular situations, this strategy can be adopted to accelerate the development of therapeutic biopharmaceuticals and their access to patients.
1
Despite differences in process performance, products from the three CHO production processes showed largely comparable primary and higher-order structures, purity, impurity profiles, biological and immunological functions, and stress-induced degradation behavior.
2
JS016, a SARS-CoV-2 spike-protein-neutralizing antibody, was developed on an accelerated four-month timeline instead of the typical 12–18 months.
3
Orthogonal and state-of-the-art analytical methods were used to establish quality and functional comparability across materials produced during different development stages.
4
The findings support sequential use of transient, mini-pool, and single-clone CHO systems to accelerate therapeutic biopharmaceutical development in appropriate situations.
5
Transient CHO cells, mini-pool-derived cells, and a single-clone working cell bank were sequentially used across preclinical, Phase 1, and later clinical development.

JS016 SARS-CoV-2-neutralizing monoclonal antibody produced using transient, mini-pool-derived, and single-clone CHO cell processes

Comparability of process performance and product quality, including molecular structure, purity and impurity profiles, biological and immunological functions, and stress-induced degradation behavior

Publication Details
Publication Date
2021-12-20
Journal
Publisher
ISSN
Cited by
17
Access Type
Author Information
Authors
Zhihao Fu
Yanping Zhu
Wenbo Wang
Xiaojuan Yu
Jialiang Du
Chun‐Yu Liu
Gang Wu
Chuanfei Yu
Gangling Xu
Lan Wang
Cexiong Fu
Hongchuan Liu
Yuan Li
Meng Li
Sha Guo
Yalan Yang
Maoqin Duan
Yongfei Cui
Hui Feng
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%